Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


The direct thrombin inhibitor hirudin

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Current use of biologicals in thrombosis and haemostasis

Issue: 2008: 99/5 (May) pp. 799-983
Pages: 819-829

The direct thrombin inhibitor hirudin

Andreas Greinacher 1, Theodore E. Warkentin2

1Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Greifswald, Germany; 2 Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada


Deep vein thrombosis, hirudin, thrombin, HIT


This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication for hirudin – anticoagulation of patients with heparin-induced thrombocytopenia (HIT) – the experience with hirudin in other indications, especially acute coronary syndromes, are briefly presented. Hirudins have been formally studied prior to their regulatory approval; however, important information on their side effects and relevant preventative measures only became available later. Therefore, current recommendations and dosing schedules for hirudin differ considerably from the information given in the package inserts. Drawbacks of hirudin and important precautions for avoiding potential adverse effects are discussed in detail in the third part of this review.

You may also be interested in...

William P. Sheffield 1,2; Louise J. Eltringham-Smith 1; Sharon Gataiance 1; Varsha Bhakta2

Thromb Haemost 2009 101 5: 867-877

Arina J. ten Cate- Hoek 1, 3, Arne W. J. H. Dielis 2, Henri M. H. Spronk 2, René van Oerle 1, Karly Hamulyák 1, Martin H. Prins 3, Hugo ten Cate2

Thromb Haemost 2008 100 2: 240-245


Rodolphe Meyer1,3, Patrice Degoulet 2,3

Yearb Med Inform 2008 : 114-127